344 related articles for article (PubMed ID: 29954621)
1. Properdin: A multifaceted molecule involved in inflammation and diseases.
Chen JY; Cortes C; Ferreira VP
Mol Immunol; 2018 Oct; 102():58-72. PubMed ID: 29954621
[TBL] [Abstract][Full Text] [Related]
2. The Role of Properdin in C5 Convertase Activity and C5b-9 Formation in the Complement Alternative Pathway.
Michels MAHM; Maas RJF; van der Velden TJAM; van de Kar NCAJ; van den Heuvel LPWJ; Volokhina EB;
J Immunol; 2021 Nov; 207(10):2465-2472. PubMed ID: 34635587
[TBL] [Abstract][Full Text] [Related]
3. Genetic and therapeutic targeting of properdin in mice prevents complement-mediated tissue injury.
Kimura Y; Zhou L; Miwa T; Song WC
J Clin Invest; 2010 Oct; 120(10):3545-54. PubMed ID: 20941861
[TBL] [Abstract][Full Text] [Related]
4. Linkage specificity and role of properdin in activation of the alternative complement pathway by fungal glycans.
Agarwal S; Specht CA; Haibin H; Ostroff GR; Ram S; Rice PA; Levitz SM
mBio; 2011; 2(5):. PubMed ID: 21878570
[TBL] [Abstract][Full Text] [Related]
5. Properdin and complement activation: a fresh perspective.
Hourcade DE
Curr Drug Targets; 2008 Feb; 9(2):158-64. PubMed ID: 18288967
[TBL] [Abstract][Full Text] [Related]
6. Recruitment of properdin by bi-specific nanobodies activates the alternative pathway of complement.
Pedersen DV; Rösner T; Hansen AG; Andersen KR; Thiel S; Andersen GR; Valerius T; Laursen NS
Mol Immunol; 2020 Aug; 124():200-210. PubMed ID: 32599335
[TBL] [Abstract][Full Text] [Related]
7. Identification of a novel mode of complement activation on stimulated platelets mediated by properdin and C3(H2O).
Saggu G; Cortes C; Emch HN; Ramirez G; Worth RG; Ferreira VP
J Immunol; 2013 Jun; 190(12):6457-67. PubMed ID: 23677468
[TBL] [Abstract][Full Text] [Related]
8. Initial properdin binding contributes to alternative pathway activation at the surface of viable and necrotic cells.
van Essen MF; Schlagwein N; van den Hoven EMP; van Gijlswijk-Janssen DJ; Lubbers R; van den Bos RM; van den Born J; Ruben JM; Trouw LA; van Kooten C;
Eur J Immunol; 2022 Apr; 52(4):597-608. PubMed ID: 35092629
[TBL] [Abstract][Full Text] [Related]
9. Properdin homeostasis requires turnover of the alternative complement pathway.
Wu X; Xu TQ; Atkinson JP
Proc Natl Acad Sci U S A; 2010 Nov; 107(45):19444-8. PubMed ID: 20974943
[TBL] [Abstract][Full Text] [Related]
10. Serum properdin consumption as a biomarker of C5 convertase dysregulation in C3 glomerulopathy.
Corvillo F; Bravo García-Morato M; Nozal P; Garrido S; Tortajada A; Rodríguez de Córdoba S; López-Trascasa M
Clin Exp Immunol; 2016 Apr; 184(1):118-25. PubMed ID: 26660535
[TBL] [Abstract][Full Text] [Related]
11. The role of properdin in complement-mediated renal diseases: a new player in complement-inhibiting therapy?
Michels MAHM; Volokhina EB; van de Kar NCAJ; van den Heuvel LPWJ
Pediatr Nephrol; 2019 Aug; 34(8):1349-1367. PubMed ID: 30141176
[TBL] [Abstract][Full Text] [Related]
12. Role of properdin in complement-mediated kidney diseases.
van Essen MF; Ruben JM; de Vries APJ; van Kooten C;
Nephrol Dial Transplant; 2019 May; 34(5):742-750. PubMed ID: 30053164
[TBL] [Abstract][Full Text] [Related]
13. Properdin: emerging roles of a pattern-recognition molecule.
Kemper C; Atkinson JP; Hourcade DE
Annu Rev Immunol; 2010; 28():131-55. PubMed ID: 19947883
[TBL] [Abstract][Full Text] [Related]
14. Properdin: a tightly regulated critical inflammatory modulator.
Blatt AZ; Pathan S; Ferreira VP
Immunol Rev; 2016 Nov; 274(1):172-190. PubMed ID: 27782331
[TBL] [Abstract][Full Text] [Related]
15. Activator-specific requirement of properdin in the initiation and amplification of the alternative pathway complement.
Kimura Y; Miwa T; Zhou L; Song WC
Blood; 2008 Jan; 111(2):732-40. PubMed ID: 17916747
[TBL] [Abstract][Full Text] [Related]
16. Isolation and characterization of rabbit properdin of the alternative complement pathway.
Nakano Y; Matsuda T; Sakamoto T; Tomita M
J Immunol Methods; 1986 Jun; 90(1):77-83. PubMed ID: 3635564
[TBL] [Abstract][Full Text] [Related]
17. Properdin in complement activation and tissue injury.
Lesher AM; Nilsson B; Song WC
Mol Immunol; 2013 Dec; 56(3):191-8. PubMed ID: 23816404
[TBL] [Abstract][Full Text] [Related]
18. Local release of properdin in the cellular microenvironment: role in pattern recognition and amplification of the alternative pathway of complement.
Cortes C; Ohtola JA; Saggu G; Ferreira VP
Front Immunol; 2012; 3():412. PubMed ID: 23335922
[TBL] [Abstract][Full Text] [Related]
19. The properdin pathway: an "alternative activation pathway" or a "critical amplification loop" for C3 and C5 activation?
Harrison RA
Semin Immunopathol; 2018 Jan; 40(1):15-35. PubMed ID: 29167939
[TBL] [Abstract][Full Text] [Related]
20. A properdin dependent nephritic factor slowly activating C3, C5, and C9 in membranoproliferative glomerulonephritis, types I and III.
Clardy CW; Forristal J; Strife CF; West CD
Clin Immunol Immunopathol; 1989 Mar; 50(3):333-47. PubMed ID: 2917424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
